Sanofi (SNY) Gains from Sales and Divestitures (2020 - 2021)

Sanofi (SNY) posted Gains from Sales and Divestitures of $1.8 billion for Q2 2021, up 24.19% sequentially from $1.4 billion in Q4 2020.

Sanofi (SNY) Gains from Sales and Divestitures (2020 - 2021) Analysis & Trends

Sanofi has reported Gains from Sales and Divestitures for 2 years, with the latest figure at $1.8 billion in Q2 2021.

Quarterly Gains from Sales and Divestitures changed N/A year-over-year to $1.8 billion in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $1.8 billion (changed N/A YoY) and the FY2020 annual result came in at $1.4 billion, changed N/A from the prior year.
Gains from Sales and Divestitures improved to $1.8 billion in Q2 2021 per SNY's latest filing, from $1.4 billion in the prior quarter.
Over five years, Gains from Sales and Divestitures peaked at $1.8 billion in Q2 2021 and troughed at $1.4 billion in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn
10	Sanofi	55.07 Bn	47.69 Bn	10.79 Bn

Download Data